321 related articles for article (PubMed ID: 34520819)
1. IDO1/TDO dual inhibitor RY103 targets Kyn-AhR pathway and exhibits preclinical efficacy on pancreatic cancer.
Liang H; Li T; Fang X; Xing Z; Zhang S; Shi L; Li W; Guo L; Kuang C; Liu H; Yang Q
Cancer Lett; 2021 Dec; 522():32-43. PubMed ID: 34520819
[TBL] [Abstract][Full Text] [Related]
2. Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn-AhR-AQP4 signaling pathway.
Du L; Xing Z; Tao B; Li T; Yang D; Li W; Zheng Y; Kuang C; Yang Q
Signal Transduct Target Ther; 2020 Feb; 5(1):10. PubMed ID: 32296044
[TBL] [Abstract][Full Text] [Related]
3. Targeting of neuroblastoma cells through Kynurenine-AHR pathway inhibition.
Dos Santos IL; Mitchell M; Nogueira PAS; Lafita-Navarro MC; Perez-Castro L; Eriom J; Kilgore JA; Williams NS; Guo L; Xu L; Conacci-Sorrell M
FEBS J; 2024 May; 291(10):2172-2190. PubMed ID: 38431776
[TBL] [Abstract][Full Text] [Related]
4. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
Kim M; Tomek P
Front Immunol; 2021; 12():636081. PubMed ID: 33708223
[TBL] [Abstract][Full Text] [Related]
5. Tryptophan depletion sensitizes the AHR pathway by increasing AHR expression and GCN2/LAT1-mediated kynurenine uptake, and potentiates induction of regulatory T lymphocytes.
Solvay M; Holfelder P; Klaessens S; Pilotte L; Stroobant V; Lamy J; Naulaerts S; Spillier Q; Frédérick R; De Plaen E; Sers C; Opitz CA; Van den Eynde BJ; Zhu J
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37344101
[TBL] [Abstract][Full Text] [Related]
6. Discovery and structure-activity relationship studies of 1-aryl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione derivatives as potent dual inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and trytophan 2,3-dioxygenase (TDO).
Pan S; Zhou Y; Wang Q; Wang Y; Tian C; Wang T; Huang L; Nan J; Li L; Yang S
Eur J Med Chem; 2020 Dec; 207():112703. PubMed ID: 32871341
[TBL] [Abstract][Full Text] [Related]
7.
Yang D; Zhang S; Fang X; Guo L; Hu N; Guo Z; Li X; Yang S; He JC; Kuang C; Yang Q
J Med Chem; 2019 Oct; 62(20):9161-9174. PubMed ID: 31580660
[TBL] [Abstract][Full Text] [Related]
8. Evaluation and comparison of the commonly used bioassays of human indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO).
Zhang S; Guo L; Yang D; Xing Z; Li W; Kuang C; Yang Q
Bioorg Chem; 2020 Nov; 104():104348. PubMed ID: 33142415
[TBL] [Abstract][Full Text] [Related]
9. Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis.
Labadie BW; Bao R; Luke JJ
Clin Cancer Res; 2019 Mar; 25(5):1462-1471. PubMed ID: 30377198
[TBL] [Abstract][Full Text] [Related]
10. Kynurenine produced by indoleamine 2,3-dioxygenase 2 exacerbates acute liver injury by carbon tetrachloride in mice.
Hoshi M; Osawa Y; Nakamoto K; Morita N; Yamamoto Y; Ando T; Tashita C; Nabeshima T; Saito K
Toxicology; 2020 May; 438():152458. PubMed ID: 32289347
[TBL] [Abstract][Full Text] [Related]
11. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine.
Campesato LF; Budhu S; Tchaicha J; Weng CH; Gigoux M; Cohen IJ; Redmond D; Mangarin L; Pourpe S; Liu C; Zappasodi R; Zamarin D; Cavanaugh J; Castro AC; Manfredi MG; McGovern K; Merghoub T; Wolchok JD
Nat Commun; 2020 Aug; 11(1):4011. PubMed ID: 32782249
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of novel tryptanthrin derivatives as dual inhibitors of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase.
Li Y; Zhang S; Wang R; Cui M; Liu W; Yang Q; Kuang C
Bioorg Med Chem Lett; 2020 Jun; 30(11):127159. PubMed ID: 32247733
[TBL] [Abstract][Full Text] [Related]
13. Discovery and biological evaluation of tanshinone derivatives as potent dual inhibitors of indoleamine 2, 3-dioxygenase 1 and tryptophan 2, 3-dioxygenase.
Liu J; Ren J; Yang K; Chen S; Yang X; Zhao QS
Eur J Med Chem; 2022 May; 235():114294. PubMed ID: 35358772
[TBL] [Abstract][Full Text] [Related]
14. Tryptophan 2,3-Dioxygenase Expression Identified in Murine Decidual Stromal Cells Is Not Essential for Feto-Maternal Tolerance.
Hoffmann D; Dvorakova T; Schramme F; Stroobant V; Van den Eynde BJ
Front Immunol; 2020; 11():601759. PubMed ID: 33363543
[TBL] [Abstract][Full Text] [Related]
15. 1-Methyl-D-tryptophan activates aryl hydrocarbon receptor, a pathway associated with bladder cancer progression.
Matheus LHG; Dalmazzo SV; Brito RBO; Pereira LA; de Almeida RJ; Camacho CP; Dellê H
BMC Cancer; 2020 Sep; 20(1):869. PubMed ID: 32907554
[TBL] [Abstract][Full Text] [Related]
16. Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.
Zhai L; Spranger S; Binder DC; Gritsina G; Lauing KL; Giles FJ; Wainwright DA
Clin Cancer Res; 2015 Dec; 21(24):5427-33. PubMed ID: 26519060
[TBL] [Abstract][Full Text] [Related]
17. Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy.
Zhang Y; Hu Z; Zhang J; Ren C; Wang Y
Eur J Med Chem; 2022 Aug; 238():114524. PubMed ID: 35696861
[TBL] [Abstract][Full Text] [Related]
18. Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
Cheong JE; Sun L
Trends Pharmacol Sci; 2018 Mar; 39(3):307-325. PubMed ID: 29254698
[TBL] [Abstract][Full Text] [Related]
19. Amyloid β neurotoxicity is IDO1-Kyn-AhR dependent and blocked by IDO1 inhibitor.
Duan Z; Zhang S; Liang H; Xing Z; Guo L; Shi L; Du L; Kuang C; Takikawa O; Yang Q
Signal Transduct Target Ther; 2020 Jun; 5(1):96. PubMed ID: 32532956
[No Abstract] [Full Text] [Related]
20. Tryptophan 2,3-dioxygenase in tumor cells is associated with resistance to immunotherapy in renal cell carcinoma.
Sumitomo M; Takahara K; Zennami K; Nagakawa T; Maeda Y; Shiogama K; Yamamoto Y; Muto Y; Nukaya T; Takenaka M; Fukaya K; Ichino M; Sasaki H; Saito K; Shiroki R
Cancer Sci; 2021 Mar; 112(3):1038-1047. PubMed ID: 33410234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
